Javier Bofill-Salvador
Sevilla, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
Journal: The New England journal of medicine
Published: January 21, 2026
UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: November 24, 2025
Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern Spain.
Journal: Frontiers in oncology
Published: October 01, 2025
Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 20, 2025
Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.
Journal: Therapeutic advances in medical oncology
Published: August 12, 2024
Targeting the Tumor Microenvironment in Breast Cancer: Prognostic and Predictive Significance and Therapeutic Opportunities.
Journal: International journal of molecular sciences
Published: October 25, 2023
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer.
Journal: International journal of molecular sciences
Published: April 04, 2023
Evaluation of Nutritional Interventions in the Care Plan for Cancer Patients: The NOA Project.
Journal: Nutrients
Published: December 12, 2022
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Journal: Breast (Edinburgh, Scotland)
Published: July 21, 2022
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
Journal: Breast (Edinburgh, Scotland)
Published: November 17, 2021
Analysis of nutritional interventions in the care process of oncological patients in Andalusia - The NOA project
Journal: Nutricion hospitalaria
Published: March 11, 2021
Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists.
Journal: Journal of drug assessment
Published: October 09, 2018
Last Updated: 09/26/2026